JP2019501202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501202A5 JP2019501202A5 JP2018535880A JP2018535880A JP2019501202A5 JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5 JP 2018535880 A JP2018535880 A JP 2018535880A JP 2018535880 A JP2018535880 A JP 2018535880A JP 2019501202 A5 JP2019501202 A5 JP 2019501202A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- reverse transcriptase
- capsid
- immunostimulants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065611A JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276722P | 2016-01-08 | 2016-01-08 | |
| US62/276,722 | 2016-01-08 | ||
| US201662343514P | 2016-05-31 | 2016-05-31 | |
| US62/343,514 | 2016-05-31 | ||
| US201662345476P | 2016-06-03 | 2016-06-03 | |
| US62/345,476 | 2016-06-03 | ||
| US201662409180P | 2016-10-17 | 2016-10-17 | |
| US62/409,180 | 2016-10-17 | ||
| US201662420969P | 2016-11-11 | 2016-11-11 | |
| US62/420,969 | 2016-11-11 | ||
| PCT/US2017/012614 WO2017120527A2 (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Division JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501202A JP2019501202A (ja) | 2019-01-17 |
| JP2019501202A5 true JP2019501202A5 (https=) | 2020-02-20 |
Family
ID=59274445
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535880A Pending JP2019501202A (ja) | 2016-01-08 | 2017-01-06 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065611A Pending JP2022087209A (ja) | 2016-01-08 | 2022-04-12 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
| JP2024076451A Pending JP2024105468A (ja) | 2016-01-08 | 2024-05-09 | Ｂ型肝炎を治療するための治療用組成物及び方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190282604A1 (https=) |
| EP (1) | EP3400008A4 (https=) |
| JP (3) | JP2019501202A (https=) |
| KR (2) | KR20250089561A (https=) |
| CN (1) | CN110022895A (https=) |
| AU (3) | AU2017205650A1 (https=) |
| BR (1) | BR112018013928A2 (https=) |
| CA (1) | CA3009996A1 (https=) |
| CL (2) | CL2018001858A1 (https=) |
| CO (1) | CO2018008249A2 (https=) |
| HK (1) | HK1255835A1 (https=) |
| IL (2) | IL295692A (https=) |
| PH (1) | PH12018501455A1 (https=) |
| SG (2) | SG10201912314QA (https=) |
| TW (4) | TW202435851A (https=) |
| WO (1) | WO2017120527A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112534055A (zh) | 2018-07-13 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 用于调节rtel1表达的寡核苷酸 |
| CA3132170A1 (en) * | 2019-04-18 | 2020-10-22 | Michael BIERMER | Combination therapy for treating hepatitis b virus infection |
| US20200332297A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| JP7706475B2 (ja) * | 2020-05-15 | 2025-07-11 | 福建▲広▼生中霖生物科技有限公司 | 三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用 |
| WO2023056933A1 (zh) * | 2021-10-08 | 2023-04-13 | 正大天晴药业集团股份有限公司 | 包含衣壳蛋白抑制剂和逆转录酶抑制剂的药物组合 |
| CN117771361B (zh) * | 2024-02-27 | 2024-06-07 | 天津中逸安健生物科技有限公司 | 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69932154T2 (de) * | 1998-02-12 | 2007-05-31 | G.D. Searle Llc, Chicago | Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen |
| AU3009801A (en) * | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
| EP1581496A4 (en) * | 2002-12-02 | 2008-04-23 | Gilead Sciences Inc | 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION |
| US20110218512A1 (en) * | 2008-06-03 | 2011-09-08 | Aethlon Medical, Inc. | Enhanced antiviral therapy methods and devices |
| PH12012501303A1 (en) * | 2009-12-31 | 2013-01-21 | Zhou xiao jian | Compositions and methods for treating hepatitis b virus infection |
| US9029341B2 (en) * | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| SG11201501255PA (en) * | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| CA2948580A1 (en) * | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
| US10358447B2 (en) * | 2017-12-04 | 2019-07-23 | Arbutus Biopharma Corporation | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same |
| US10550084B2 (en) * | 2017-12-04 | 2020-02-04 | Arbutus Biopharma Corporation | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same |
-
2017
- 2017-01-06 IL IL295692A patent/IL295692A/en unknown
- 2017-01-06 SG SG10201912314QA patent/SG10201912314QA/en unknown
- 2017-01-06 US US16/068,243 patent/US20190282604A1/en not_active Abandoned
- 2017-01-06 AU AU2017205650A patent/AU2017205650A1/en not_active Abandoned
- 2017-01-06 KR KR1020257018649A patent/KR20250089561A/ko active Pending
- 2017-01-06 CN CN201780014167.5A patent/CN110022895A/zh active Pending
- 2017-01-06 WO PCT/US2017/012614 patent/WO2017120527A2/en not_active Ceased
- 2017-01-06 JP JP2018535880A patent/JP2019501202A/ja active Pending
- 2017-01-06 EP EP17736471.8A patent/EP3400008A4/en not_active Withdrawn
- 2017-01-06 SG SG11201805729SA patent/SG11201805729SA/en unknown
- 2017-01-06 BR BR112018013928-9A patent/BR112018013928A2/en not_active Application Discontinuation
- 2017-01-06 KR KR1020187022434A patent/KR20180120675A/ko not_active Ceased
- 2017-01-06 IL IL303754A patent/IL303754A/en unknown
- 2017-01-06 HK HK18114911.7A patent/HK1255835A1/zh unknown
- 2017-01-06 CA CA3009996A patent/CA3009996A1/en active Pending
- 2017-01-09 TW TW112146636A patent/TW202435851A/zh unknown
- 2017-01-09 TW TW110121989A patent/TW202211912A/zh unknown
- 2017-01-09 TW TW111130283A patent/TW202322791A/zh unknown
- 2017-01-09 TW TW106100606A patent/TW201735950A/zh unknown
-
2018
- 2018-07-06 PH PH12018501455A patent/PH12018501455A1/en unknown
- 2018-07-06 CL CL2018001858A patent/CL2018001858A1/es unknown
- 2018-08-03 CO CONC2018/0008249A patent/CO2018008249A2/es unknown
-
2022
- 2022-04-12 JP JP2022065611A patent/JP2022087209A/ja active Pending
- 2022-06-02 AU AU2022203814A patent/AU2022203814A1/en not_active Abandoned
- 2022-11-29 US US18/071,353 patent/US20240050463A1/en active Pending
-
2023
- 2023-03-28 CL CL2023000892A patent/CL2023000892A1/es unknown
-
2024
- 2024-05-09 JP JP2024076451A patent/JP2024105468A/ja active Pending
-
2025
- 2025-08-14 AU AU2025217340A patent/AU2025217340A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501202A5 (https=) | ||
| Nilsson-Payant et al. | The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication | |
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| JP2016531144A5 (https=) | ||
| Ouyang et al. | lncRNAs regulate the innate immune response to viral infection | |
| JP2019068829A5 (https=) | ||
| ZA202106848B (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| IL295692A (en) | Medical preparations and methods for treating jaundice b | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| GEP20217282B (en) | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| CY1106207T1 (el) | Αντιιικα παραγωγα νουκλεοζιτων | |
| JP2019511542A5 (https=) | ||
| JP2006141398A5 (https=) | ||
| JP2019530462A5 (https=) | ||
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| JP2018507877A5 (https=) | ||
| JP2017536344A5 (https=) | ||
| JP2016128507A5 (https=) | ||
| WO2010081082A3 (en) | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | |
| JP2018512041A5 (https=) | ||
| JP2016508134A5 (https=) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2015513535A5 (https=) | ||
| EA201500748A1 (ru) | Ингибирующие олигонуклеотиды и их применение в терапии |